SCHEMBL7667779

SCHEMBL7667779

Cc1ccc(Nc2ccc(S(=O)(=O)N[C@H](C)C(=O)OCc3ccccc3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.52
ALDH1A1 P00352 4/20 0.51
AR P10275 1/20 0.51
GAA P10253 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
CA2 P00918 5/20 0.49
CA1 P00915 4/20 0.49
LMNA P02545 1/20 0.49
ADAMTS4 O75173 2/20 0.49
MMP13 P45452 2/20 0.48
HSD17B10 Q99714 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
MAPT P10636 1/20 0.46
CA7 P43166 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30689105 0.94 ALDH1A1 (0.56) MMP9ALDH1A1ARGAACA2
SCHEMBL7667775 0.88 MMP9 (0.66) MMP9ALDH1A1MEN1KMT2ALMNA
SCHEMBL5221010 0.83 LMNA (0.55) MMP9ALDH1A1ARGAACA2
SCHEMBL30689139 0.82 ALDH1A1 (0.54) MMP9ALDH1A1ARGAACA2
SCHEMBL30689121 0.82 ADAMTS4 (0.60) MMP9ALDH1A1GAACA2CA1
SCHEMBL5572756 0.81 CTSL (0.58) MMP9ALDH1A1GAACA2ADAMTS4
SCHEMBL29883707 0.80 CTSL (0.54) MMP9ALDH1A1MEN1KMT2ACA2
SCHEMBL30689129 0.80 ALDH1A1 (0.52) MMP9ALDH1A1GAAMEN1KMT2A
SCHEMBL20335059 0.80 CTSL (0.68) MMP9ALDH1A1GAACA2ADAMTS4
SCHEMBL30689103 0.80 CTSL (0.56) MMP9ALDH1A1CA2CA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed